Scoglio Daniele, Walker Avery S, Fichera Alessandro
Department of Surgery, University of Washington Medical Center, Seattle, Washington.
Department of Surgery, Madigan Army Medical Center, Fort Lewis, Washington.
Clin Colon Rectal Surg. 2014 Dec;27(4):172-81. doi: 10.1055/s-0034-1394156.
Anal fistula (AF) presents a chronic problem for patients and colorectal surgeons alike. Surgical treatment may result in impairment of continence and long-term risk of recurrence. Treatment options for AFs vary according to their location and complexity. The ideal approach should result in low recurrence rates and minimal impact on continence. New technical approaches involving biologically derived products such as biological mesh, fibrin glue, fistula plug, and stem cells have been applied in the treatment of AF to improve outcomes and decrease recurrence rates and the risk of fecal incontinence. In this review, we will highlight the current evidence and describe our personal experience with these novel approaches.
肛瘘(AF)对患者和结直肠外科医生来说都是一个长期存在的问题。手术治疗可能导致控便功能受损以及长期复发风险。肛瘘的治疗方案因其位置和复杂性而异。理想的治疗方法应能降低复发率,并对控便功能影响最小。涉及生物衍生产品(如生物补片、纤维蛋白胶、肛瘘栓和干细胞)的新技术方法已应用于肛瘘治疗,以改善治疗效果、降低复发率和大便失禁风险。在本综述中,我们将重点介绍当前的证据,并描述我们在这些新方法方面的个人经验。